Sandra Eloranta

Cancer survivorship is the field of research that includes issues that revolve around the patients' journey from the time of diagnosis, the subsequent treatment period and then on in life as a cancer survivor. In this field, questions such as are linked to how you feel after your treatment important for both patients, relatives and caregivers. As new treatment options become available, it is important to investigate how these treatments affect patients in the long term as well. Today, it is unusual for cancer treatment and patient return visits to be individually tailored, taking into account the possible future risk of long-term complications Lymphoma is a collective name for cancers that arise in our lymphatic system. Different types of lymphoma can differ significantly in terms of symptoms, diagnostics and treatment, but common to all lymphoma diseases is that they are often treated with chemotherapy. However, the treatment itself can mean that the patients have difficulty having children in the future, as well as lead to an increased risk of both heart disease and new forms of cancer several years after the treatment. As lymphoma is the fourth most common form of cancer among young people, it is particularly important to understand how to both promote early detection of late effects but also reduce the risk overall. The aim of the project is to investigate several important aspects of lymphoma survival

the possibility of having children after various lymphoma treatments, as well as the risk of suffering from heart disease or a new cancer later in life. By using new types of models, with this project we want to increase the current state of knowledge regarding these late effects by identifying particularly vulnerable patient groups that would benefit most from long-term clinical follow-up. There is currently a lack of national follow-up programs aimed at early detection of late effects among lymphoma patients, but we hope that results from these studies can contribute to new such guidelines.

Among people under the age of 40, lymphoma is the fourth most common type of cancer. Lymphoma is a collective name for cancers that occur in the cells that make up our lymphatic system. Different types of lymphoma can differ significantly in terms of symptoms, diagnosis and treatment, but common to all lymphoma diseases is that they are often treated with cytotoxic drugs. If effective treatment is started at the right time, the prognosis is often good. However, the treatment itself can lead to patients finding it more difficult to have children in the future. As lymphoma affects young patients, issues related to childbirth are therefore very relevant for both caregivers and patients. The purpose of the project is to investigate young lymphoma survivors' ability to have children after different types of lymphoma treatment and to study whether the children born after completion of treatment are healthy. As lymphoma is, after all, relatively uncommon, we will include lymphoma patients from three Nordic countries in order to increase the size and reliability of the studies. This allows us to compare how the possibility of having children is affected based on the type of lymphoma and how intensive chemotherapy has been used. We will also study childbirth according to relatively unusual types of lymphoma, and whether the chances of having children are different for women and men. Young lymphoma patients often express a concern about the effect their cancer and planned treatment will have on the chances of having children later in life, and the health of their future children. For the patient groups that will be included in these studies, there is currently a lack of sufficient scientific evidence to address this type of question. The aim of the project is therefore to increase the state of knowledge regarding lymphoma treatment and its impact on future childbirth. This in turn can assist in decision-making regarding guidelines for lymphoma treatment as well as recommendations regarding fertility counseling and fertility-preserving treatment in lymphoma patients.

Among people under the age of 40, lymphoma is the fourth most common type of cancer. Lymphoma is a collective name for cancers that occur in the cells that make up our lymphatic system. Different types of lymphoma can differ significantly in terms of symptoms, diagnosis and treatment, but common to all lymphoma diseases is that they are often treated with cytotoxic drugs. If effective treatment is started at the right time, the prognosis is often good. However, the treatment itself can lead to patients finding it more difficult to have children in the future. As lymphoma affects young patients, issues related to childbirth are therefore very relevant for both caregivers and patients. The purpose of the project is to investigate young lymphoma survivors' ability to have children after different types of lymphoma treatment and to study whether the children born after completion of treatment are healthy. As lymphoma is, after all, relatively uncommon, we will include lymphoma patients from three Nordic countries in order to increase the size and reliability of the studies. This allows us to compare how the possibility of having children is affected based on the type of lymphoma and how intensive chemotherapy has been used. We will also study childbirth according to relatively unusual types of lymphoma, and whether the chances of having children are different for women and men. Young lymphoma patients often express a concern about the effect their cancer and planned treatment will have on the chances of having children later in life, and the health of their future children. For the patient groups that will be included in these studies, there is currently a lack of sufficient scientific evidence to address this type of question. The aim of the project is therefore to increase the state of knowledge regarding lymphoma treatment and its impact on future childbirth. This in turn can assist in decision-making regarding guidelines for lymphoma treatment as well as recommendations regarding fertility counseling and fertility-preserving treatment in lymphoma patients.